Peptide Central
What tesamorelin is, how it is classified, its development status, and what published research does and does not establish.
Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH), the 44-amino-acid peptide the hypothalamus releases to signal the pituitary. It carries a trans-3-hexenoyl group at the N-terminus, a modification made to stabilise the molecule. The catalogue record gives about 5,135.9 Da and CAS 218949-48-5.
It is a GHRH-receptor agonist peptide. It is not growth hormone itself, and it is a different class of molecule from the ghrelin-receptor agonists it is often listed beside.
"Tesamorelin" names the peptide. "Tesamorelin acetate" is its acetate salt, which is the form used in the licensed pharmaceutical product. Listings sold as pens, or under a brand name, describe other products, not this catalogue item.
Lyophilised powder in a single-compound vial, listed on the tesamorelin 10mg product page.
A licensed pharmaceutical form of tesamorelin exists in some jurisdictions, approved for a specific indication in HIV-associated lipodystrophy. That approval attaches to a particular product, indication and patient population. It does not extend to the research material supplied here, and nothing on this page implies a UK licence or availability for human use.
The catalogue item is a laboratory reagent, supplied for non-clinical in-vitro research only.
The distinction matters because much of what is written online about tesamorelin describes the licensed product's clinical programme. Those documents answer questions about a medicine, a prescriber and a diagnosed population. A research reagent has none of those, which is why this page keeps the two apart.
Preclinical literature that is specific to tesamorelin is small. Most of what is published concerns the pharmaceutical product in human studies, so there is little animal or cell data to anchor claims about a research reagent.
Randomised, placebo-controlled trials of the pharmaceutical product exist in HIV-associated lipodystrophy. One example is a 50-participant trial reported by Braun and colleagues in 2017. Those results belong to that product, that population and that clinical setting. They cannot be carried over to a different material, population or purpose.
| Compound | Class | Target |
|---|---|---|
| Tesamorelin | 44-amino-acid GHRH analogue | GHRH receptor |
| CJC-1295 | Modified GHRH-derived analogue | GHRH receptor |
| Ipamorelin | Short pentapeptide | Ghrelin receptor |
A batch certificate reports the identity and measured purity of the batch tested. The product record lists batch 100241 with an HPLC purity of 99.1%, and the report is published in the COA library. A certificate says nothing about biological effect and does not extend to other batches.
The guides to reading a peptide COA and understanding HPLC purity explain what those figures can and cannot show. The growth hormone category and the tesamorelin buying guide cover the catalogue side.
Materials sold on this site are supplied solely for non-clinical in-vitro laboratory research. They must not be ingested, injected, inhaled, applied or otherwise administered to a human or animal.
We do not provide dosing, routes of administration, treatment guidance, cosmetic-use guidance or in-vivo protocols. Preparation, storage and handling must follow a validated institutional SOP, the material documentation and an appropriate risk assessment.
How Semax and Selank differ on structure, origin, classification and evidence tier, and where a direct comparison breaks down.
Research DocumentationWhat retatrutide is, how it is classified, where its development stands, and what published research does and does not establish.
Site materials are supplied solely for non-clinical in-vitro laboratory research. They must not be used in or on humans or animals. We do not provide dosing, routes of administration, treatment, cosmetic-use or in-vivo guidance. Read the legal and research-use terms.
